We have several Clinical Studies on-going at our clinic, which all have necessary Ethics Committee approvals.
All our current Clinical Studies are Industry-sponsored and therefore are at no cost to patients. Patients successfully recruited into some of our studies can even be reimbursed for travel and accommodation expenses. Maximum amounts reimbursed are specific to each Clinical Study and patients are provided with all relevant details in writing. Patients interested in participating from our Clinical Studies can phone our clinic to request an appointment to assess their suitability for any of the ongoing Clinical Studies. A referral is not always necessary. However, a clinic letter or an Optician/Optometrist email or letter stating vision in each eye and confirming the diagnosis and can sometimes save the patient an unnecessary screening visit.
Prof. Stanga is our Principal Investigator (PI) and lead surgeon for all our Clinical Studies. Prof. Stanga is supported by his dedicated Retinal Research Team.
To enter one of our Clinical Studies at The Retina Clinic London, or for more information, please send us an enquiry using the form at the bottom of this page or email us on info@theretinacliniclondon.com. You can also call us on 02045485310.
We are currently enrolling patients with the following conditions in on-site clinical trials at The Retina Clinic London:
- Dry Age-Related Macular Degeneration
- Wet Age-Related Macular Degeneration
- Vitreous Floaters
- Diabetic Macular Oedema
- X-Linked Retinitis Pigmentosa
- Usher 1B Syndrome
We will soon be enrolling patients in the following studies at The Retina Clinic London:
- Intermediate Age-Related Macular Degeneration
- Stargardt Disease
Available Trials
Patients with the following conditions can participate in one of the Clinical Studies at The Retina Clinic London:
Geographic Atrophy secondary to Dry Age-Related Macular Degeneration
A single intravitreal injection of gene therapy which aims to reduce the rate of progression of the disease. Eligible patients are randomised to treatment or placebo (2:1).
Key inclusion criteria:
- Age 60 or older
- Snellen Visual Acuity: 6/95 or better
Key exclusion criteria:
- History of Wet AMD in either eye
- Have previously received gene therapy of any kind
Wet Age-Related Macular Degeneration with previous treatment
A gene therapy surgery which aims to reduce the burden of intravitreal injections. Eligible patients will be randomised to gene therapy or Anti-VEGF injections control group (2:1). Patients in the control group have the opportunity to also receive the gene therapy after 1 year.
Key inclusion criteria:
- Age between 50 and 89
- Received a diagnosis of Wet AMD within 4 years in the study eye
- Have already had cataract surgery in the eye with Wet AMD
Key exclusion criteria:
- Have previously received gene therapy of any kind
Vitreous Floaters and Opacities (VFO)
This aims to determine the best type of Vitreous Floaters and Opacities (VFO) that can be treated with Nd:YAG vitreolysis laser therapy, which is already a commercially approved treatment for VFO.
Key inclusion criteria:
- Age 18 or older
- Suffering from symptomatic vitreous floaters
- Either:
- Myopic
- Have had a posterior vitreous detachment (PVD)
Key exclusion criteria:
- Significant cataract
- Intraocular surgery within 6 months
Intermediate Age-Related Macular Degeneration
To assess the safety and efficacy of two treatment protocols of retinal laser in the treatment of intermediate age-related macular degeneration.
Key inclusion criteria:
- Age 50 or older
- Intermediate AMD
Key exclusion criteria:
- Advanced AMD
X-Linked Retinitis Pigmentosa
A gene therapy trial for male patients with X-Linked Retinitis Pigmentosa (XLRP). Randomised to gene therapy surgery or untreated control group (2:1).
Key inclusion criteria:
- Age between 12 and 50
- Diagnosis of XLRP
Key exclusion criteria:
- Have previously received gene therapy of any kind
Usher 1B Syndrome
A gene therapy trial for patients with Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa. All patients receive treatment in this trial.
Key inclusion criteria:
- Age between 18 and 50
- Molecular diagnosis of USH1B due to MYO7A mutations
Key exclusion criteria:
- Have previously received gene therapy of any kind